1. Home
  2. LCID vs ACAD Comparison

LCID vs ACAD Comparison

Compare LCID & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lucid Group Inc.

LCID

Lucid Group Inc.

HOLD

Current Price

$5.71

Market Cap

3.7B

ML Signal

HOLD

Logo ACADIA Pharmaceuticals Inc.

ACAD

ACADIA Pharmaceuticals Inc.

HOLD

Current Price

$22.09

Market Cap

3.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LCID
ACAD
Founded
2007
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.7B
3.8B
IPO Year
2020
2000

Fundamental Metrics

Financial Performance
Metric
LCID
ACAD
Price
$5.71
$22.09
Analyst Decision
Hold
Buy
Analyst Count
7
22
Target Price
$15.71
$30.55
AVG Volume (30 Days)
16.9M
1.4M
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
69.12
EPS
N/A
2.30
Revenue
$595,271,000.00
$726,437,000.00
Revenue This Year
$71.67
$18.80
Revenue Next Year
$89.72
$11.70
P/E Ratio
N/A
$9.87
Revenue Growth
N/A
40.45
52 Week Low
$1.97
$14.20
52 Week High
$25.22
$28.35

Technical Indicators

Market Signals
Indicator
LCID
ACAD
Relative Strength Index (RSI) 22.73 50.68
Support Level $2.11 $21.51
Resistance Level $10.97 $22.97
Average True Range (ATR) 0.58 0.66
MACD -0.19 0.08
Stochastic Oscillator 1.56 65.03

Price Performance

Historical Comparison
LCID
ACAD

About LCID Lucid Group Inc.

Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It offers its own geographically distributed retail and service locations and through direct-to-consumer online and retail sales. It also boasts a product roadmap of future vehicle programs and technologies. It focuses on in-house hardware and software innovation, vertical integration, and a clean-sheet approach to engineering and design led to the development of the Lucid Air. The Lucid Air is a luxury sedan that redefines both the luxury car segment and the EV space. Its geographic segments include North America, the Middle East, and Other International.

About ACAD ACADIA Pharmaceuticals Inc.

Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.

Share on Social Networks: